Skip to main content

Table 1 Characteristics of 11 eligible studies in this meta-analysis

From: Poor prognosis of nucleophosmin overexpression in solid tumors: a meta-analysis

Author

Year

Study region

Cancer type

NO. of patients

Age, median (range)

Male/ female

Cancer stage or grade

Percentage of high NPM Cutoff value

Follow-up months

HR and 95% CI

Quality score

Kazutaka Kikuta [30]

2009

Japan

Ewing’s sarcoma

34

20(1–63)

22/12

Stage I-III

23/34(68%), NA

57.5 (8–179)

NA

6

Yan Liu [3]

2012

China

Colon cancer

31

NA

13/18

NA

19/31(61%), H-score ≥ 3

NA

NA

9

Shao-Jung Lo [31]

2013

Taiwan

Hepatocellular carcinoma

110

NA

75/35

Stage I-IV

17/110(15%), score 3

NA

HR: 1.92 CI (0.92–4.02) P = 0.082

9

Yong Li [25]

2014

China

Gastric cancer

108

NA

76/32

Stage I-IV

57/108(53%), score 5–12

31(3–53)

HR: 1.970 CI (1.134–3.422) P = 0.0162

9

Ambrogio P. Londero [15]

2014

Italy

Ovarian serous cancer

73

NA

0/73

Stage I-IV

NA, H-score > 10

39(22–57)

HR: 2.98 CI (1.46–6.08) P < 0.05

7

Yu-Feng Yang [26]

2014

China

Colorectalcarcinomas

161

NA

90/71

Grade 1–3

104/161(64.6%), > 50%

49.24 (23–81)

HR: 1.919 CI (1.056–3.488) P = 0.032

9

Jian-Guo Chen [27]

2015

China

Glioma

90

NA

58/32

Grade II-IV

50/90(55.6%), H-score ≥ 5

NA

HR: 2.380 CI (1.149–4.929) P = 0.020

9

Yen-Hsin Kuo [32]

2015

Taiwan

Astrocytoma

99

NA

51/48

Grade I-IV

51/99(51.5%), > 50%

NA

NA

9

Yi Zhu [28]

2015

China

Pancreatic ductal adenocarcinoma

65

62(34–85)

40/25

Grade 1,2,4

46/65(69%), H-score ≥ 4

12(0.6–87)

NA

7

Fang Zhou [14]

2016

China

gastric cancer

131

63.5(28–85)

96/35

Stage I-III

86/131(66%), H-score ≥ 5

39(3–55)

NA

9

Hai-Ping Wang [29]

2017

China

Bladder urothelial carcinoma

95

NA

66/29

NA

67/95(70.5%), NA

81.5 (60–105)

NA

8